Newswise — Leading Cardiologists to Address Recent Controversies on Two Hot Topics -Safety Concerns Surrounding Drug-Eluting Stents and Carotid Stenting
Interactive Q&A press briefings to be held on Wednesday, October 25 at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C
Wednesday, October 25, 12:30-1:00 p.m.
CAROTID STENTING: AN OPEN QUESTIONRecent Controversy Over Carotid Stenting Addressed by Top Interventional Cardiologists at TCT 2006 Press Conference
Two recent European studies have raised concerns about the safety and efficacy of carotid stenting in symptomatic patients, but leading interventional cardiologists say it's still an open question, and will address the issue at a special press conference."¢ What do the European trials The French EVA-3S study and German SPACE trial tell us about carotid stenting on symptomatic patients?"¢ What is being done in the U.S. to answer questions about carotid stenting as an alternative to carotid surgery?"¢ When can we expect definitive answers from U.S. trials?
WHO: The press conference will be moderated by William A. Gray, M.D., Director of Endovascular Services at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Associate Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons. The press conference panelists will be:
"¢ L. Nelson Hopkins, M.D., Professor of Neurosurgery and Radiology and Chairman of Neurosurgery at the University at Buffalo, State University of New York"¢ Subbarao Myla, M.D., Medical Director, Fountain Valley Heart and Vascular Center"¢ Klaus Mathias, M.D., Clinic Center Middle Dortmund, Dortmund, Germany"¢ Jay Yadav, M.D., Chairman of CardioMEMS Inc."¢ Michael Jaff, D.O., F.A.C.C., Massachusetts General Hospital
Wednesday, October 25, 2:00-2:30 p.m.
DRUG ELUTING STENTS: Where do we go from here?
Top Experts to Provide Perspective on Late Stent Thrombosis at TCT 2006 Press Conference
The safety of drug-eluting stents (DES) is a hotly discussed topic at the Transcatheter Cardiovascular Therapeutics Symposium (TCT 2006), and a panel of the world's top interventional cardiologists will answer questions regarding the concerns at a special press conference Wednesday. The experts will provide perspective on recent data regarding late stent thrombosis and address key questions including:"¢ Are certain types of patients better candidates for DES than others?"¢ Should DES be used off-label?"¢ Why do data analyses differ?"¢ Might risks vary with different stents?"¢ Might additional studies be needed to better understand DES risks?"¢ What should doctors tell patients about bare metal stents vs. drug-eluting stents?
WHO: The press conference will be moderated by:"¢ Martin B. Leon, M.D., Professor of Medicine at Columbia University College of Physicians and Surgeons and Associate Director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center"¢ Jeffrey W. Moses, M.D., Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical CenterThe press conference panelists will be:"¢ Stephen G. Ellis, M.D., Director, Sones Cardiac Cath Lab, The Cleveland Clinic Foundation"¢ Barry F. Uretsky, M.D., Chief, Division of Cardiology, University of Texas Medical Branch"¢ William W. O'Neill, M.D., Executive Dean for Clinical Affairs, Leonard M. Miller School of Medicine, University of Miami"¢ Spencer B. King, III, M.D., M.A.C.C., Fuqua Chair of Interventional Cardiology, Fuqua Heart Center at Piedmont Hospital, Professor of Medicine Emeritus in Cardiology, Emory University School of Medicine.
RSS